- Home
- IMCR vs BCSF Comparison
IMCR vs BCSF Comparison
Compare IMCR & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BCSF
- Stock Information
- Founded
- IMCR 2008
- BCSF 2015
- Country
- IMCR United Kingdom
- BCSF United States
- Employees
- IMCR N/A
- BCSF N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BCSF Finance/Investors Services
- Sector
- IMCR Health Care
- BCSF Finance
- Exchange
- IMCR Nasdaq
- BCSF Nasdaq
- Market Cap
- IMCR 1.4B
- BCSF 1.2B
- IPO Year
- IMCR 2021
- BCSF 2018
- Fundamental
- Price
- IMCR $29.58
- BCSF $16.70
- Analyst Decision
- IMCR Buy
- BCSF Hold
- Analyst Count
- IMCR 12
- BCSF 4
- Target Price
- IMCR $63.00
- BCSF $17.50
- AVG Volume (30 Days)
- IMCR 372.8K
- BCSF 446.7K
- Earning Date
- IMCR 05-07-2025
- BCSF 05-05-2025
- Dividend Yield
- IMCR N/A
- BCSF 0.72%
- EPS Growth
- IMCR N/A
- BCSF N/A
- EPS
- IMCR N/A
- BCSF 1.85
- Revenue
- IMCR $310,202,000.00
- BCSF $292,653,000.00
- Revenue This Year
- IMCR $18.97
- BCSF N/A
- Revenue Next Year
- IMCR $8.43
- BCSF N/A
- P/E Ratio
- IMCR N/A
- BCSF $9.03
- Revenue Growth
- IMCR 24.36
- BCSF N/A
- 52 Week Low
- IMCR $27.19
- BCSF $15.29
- 52 Week High
- IMCR $66.00
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- IMCR 49.95
- BCSF 36.64
- Support Level
- IMCR $28.92
- BCSF $16.30
- Resistance Level
- IMCR $30.04
- BCSF $17.04
- Average True Range (ATR)
- IMCR 1.49
- BCSF 0.33
- MACD
- IMCR 0.10
- BCSF 0.01
- Stochastic Oscillator
- IMCR 53.71
- BCSF 35.71
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.